Quick Answer
Alaunos Therapeutics, Inc. reported Net Income Loss of -$4.18 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +10.8% in Net Income Loss from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2007 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: -$8.90 million | Q1 2014: -$9.71 million | Q2 2014: -$5.58 million | Q3 2014: -$6.09 million | Q4 2014: -$10.40 million | Q1 2015: -$78.23 million | Q2 2015: -$14.21 million | Q3 2015: -$18.17 million | Q4 2015: -$9.48 million | Q1 2016: -$12.02 million | Q2 2016: -$131.20 million | Q3 2016: -$14.45 million | Q4 2016: -$14.76 million | Q1 2017: -$19.66 million | Q2 2017: -$17.73 million | Q3 2017: -$17.60 million | Q4 2017: -$18.27 million | Q1 2018: -$21.14 million | Q2 2018: -$17.49 million | Q3 2018: -$18.66 million | Q4 2018: $194.54 million | Q1 2019: -$13.43 million | Q2 2019: -$14.62 million | Q3 2019: -$74.00 million | Q4 2019: -$15.75 million | Q1 2020: -$18.29 million | Q2 2020: -$18.60 million | Q3 2020: -$20.32 million | Q4 2020: -$22.77 million | Q1 2021: -$21.55 million | Q2 2021: -$22.67 million | Q3 2021: -$22.73 million | Q1 2022: -$9.79 million | Q2 2022: -$9.93 million | Q3 2022: -$8.85 million | Q1 2023: -$10.05 million | Q2 2023: -$8.77 million | Q3 2023: -$8.48 million | Q1 2024: -$1.68 million | Q2 2024: -$1.13 million | Q3 2024: -$1.13 million | Q1 2025: -$1.07 million | Q2 2025: -$1.05 million | Q3 2025: -$1.16 million.
- Over the full 19 years of available data (2007 to 2025), Alaunos Therapeutics, Inc.'s Net Income Loss has grown by 84.3%.
- Historical annual values: Fiscal year 2025: -$4.18 million | Fiscal year 2024: -$4.68 million | Fiscal year 2023: -$4.68 million | Fiscal year 2022: -$37.73 million | Fiscal year 2021: -$78.75 million | Fiscal year 2020: -$79.98 million | Fiscal year 2019: -$117.80 million | Fiscal year 2018: -$53.12 million | Fiscal year 2017: -$54.32 million | Fiscal year 2016: -$165.30 million | Fiscal year 2015: -$120.09 million | Fiscal year 2014: -$31.78 million | Fiscal year 2013: -$57.11 million | Fiscal year 2012: -$96.13 million | Fiscal year 2011: -$63.78 million | Fiscal year 2010: -$32.67 million | Fiscal year 2009: -$7.65 million | Fiscal year 2008: -$25.23 million | Fiscal year 2007: -$26.61 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: